I
NTLA icon

InceptionR’s Intellia Therapeutics NTLA Stock Holding History

InceptionR’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375K Buy
+22,141
New +$310K 0.09% 403
2025
Q3 		– Sell
-16,210
Closed -$152K – 865
2025
Q2 		$152K Buy
+16,210
New +$133K 0.04% 590

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

InceptionR's NTLA Position: Q2 2026 in Review

InceptionR opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 22,141 shares worth $375K. The stake represents 0.09% of the portfolio and ranks #403 among its holdings. This is a return to the name: InceptionR previously reported a position in NTLA as recently as Q2 2025.

InceptionR first reported a position in NTLA in Q2 2025 and has held it in 2 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • InceptionR held 22,141 shares of Intellia Therapeutics worth $375K as of Q2 2026.
  • Intellia Therapeutics was a new InceptionR position in Q2 2026.
  • Intellia Therapeutics made up 0.09% of InceptionR's portfolio in Q2 2026, its #403 holding.
  • InceptionR first reported a position in Intellia Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on InceptionR's 13F filing for Q2 2026, filed 11 Aug 2026.